A nutritional supplement to fill nutrient gaps and support gut health for people taking GLP-1 medications.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, triple-blind, placebo-controlled trial will enroll 120 adults on stable GLP-1 receptor agonist therapy to compare a daily nutritional supplement (AG1) against a matching placebo. Eligible participants are aged 18–59 with BMI 20–31.9 and on a maintenance GLP-1 dose for at least eight weeks; they will follow a standardized protocol including blood draws and stool sampling for microbiome analysis. Participants must duplicate their diet for 72 hours before blood tests, refrain from caffeine and exercise for 24 hours, and fast for 10 hours prior to testing, and they are asked to maintain usual diet, sleep, and activity and avoid other supplements during the trial. Study visits are conducted at Citruslabs in Santa Monica, California.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Be male or female
* Be aged 18-59.
* Has a BMI between 20-31.9.
* Anyone currently taking GLP-1 medication at their maintenance dose (week 8+), and without any plans to alter their dosage. This includes: Semaglutide (Ozempic®, Wegovy®, Rybelsus®), Liraglutide (Saxenda®, Victoza®), Dulaglutide (Trulicity®), Exenatide (Byetta®, Bydureon®), Lixisenatide (Adlyxin®)
* Anyone willing to follow the study protocol, including immediately prior to the all blood tests, duplicating their diet for 72 hours (3 days), refraining from caffeine and exercise for 24 hours, and fasting for 10 hours.
* Anyone willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial.
* Anyone willing to avoid introducing any other supplements, medications, or herbal remedies for the duration of this trial.
* Anyone who is generally healthy - does not live with any diagnosed uncontrolled chronic disease.
* Has access to a consistent weighing scale for the duration of the study.
* Resides in the United States.

Exclusion Criteria:

* Anyone with a diagnosis of Type I or Type II diabetes.
* Anyone with a diagnosis of any metabolic health condition, such as hypertension and dyslipidemia.
* Anyone who has taken any multivitamin/multimineral supplements within the past 3 months.
* Anyone who has taken a probiotic supplement within the past month.
* Anyone who has regularly consumed (5 days/week or more) products that target healthy aging, anti-aging, longevity, gut health, energy, or ingestive behaviour (such as cravings), including resveratrol, quercetin, pterostilbene, coQ10, grapefruit, nicotinamide riboside, prebiotic fiber, green tea, niacin (vitamin B3) within the past 2 months.
* Anyone who has received an antibiotic, antifungal, antiparasitic, or antiviral treatment within the past 90 days.
* Anyone who has a known history of severe digestive disorders or metabolic conditions that impact nutrient absorption or metabolism, including acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, a history of colon resection, gastroparesis, Inborn errors of metabolism (such as PKU), or gastrointestinal tract surgeries.
* Anyone with any known allergies or hypersensitivities to any supplement product ingredients.
* Anyone with any chronic health conditions that could impact participation in this study, such as asthma, gout, fibromyalgia, chronic inflammatory conditions (such as Crohn's, Lupus, HIV/AIDS), thyroid conditions, cancer (within the past 5 years), mental health disorders, history of serious illness in the last three months, history of substance abuse, or planned surgery during the study period.
* Anyone currently pregnant, trying to conceive, or breastfeeding.
* Anyone who has undergone a change in hormone therapy (including oral contraceptives) within the past 4 weeks, or is unwilling to maintain their current hormone therapy/oral contraceptive use throughout the course of the study.
* Anyone who consumes more than 2 standard alcoholic drinks per day or more than 10 drinks per week, or has within the past 6 months.
* Anyone who is currently a smoker or has been a smoker within the past month.
* Anyone who follows a specific exclusion diet, including vegan, vegetarian, carnivore, paleo, atkins, or ketogenic.

Where it's running

• Citruslabs
  Santa Monica, California, United States Recruiting

Study contacts

• Study coordinator: Ellen O'Gorman
• Email: ellen@citruslabs.com
• Phone: (805) 292-0714

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ubiquinol to See if It Reduces Fatigue for Adults Using GLP-1 Weight-Loss Meds

  A daily ubiquinol supplement is tested to see if it lowers fatigue and helps keep muscle strength in adults taking GLP-1 weight-loss medicines.

  Recruiting StudySetGo · Glasgow · NCT07789106

• Discontinuation timing of GLP-1 receptor agonists before colonoscopy

  This study tests whether stopping GLP-1 receptor agonists for either 0 or 7 days before colonoscopy affects bowel prep quality and the need for a repeat procedure in adults undergoing colonoscopy.

  Recruiting Fu Jen Catholic University Hospital · New Taipei, Taiwan · NCT07736963

• Should GLP-1 receptor agonists be stopped a week before an endoscopy?

  A one-week pause of long-acting GLP-1 receptor agonists is being tested to see if it improves gastric prep quality and reduces the need for repeat endoscopy in adults undergoing EGD.

  Recruiting Phase 3 Fu Jen Catholic University Hospital · New Taipei City, Taiwan · NCT07736911

• Gut microbes and blood signals in sepsis-related liver and kidney injury

  This study tests whether gut microbes and blood markers differ in adults with sepsis who develop liver or kidney injury, compared with healthy volunteers.

  Recruiting at 6 sites First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang and 5 other locations · NCT07735182

• Plant-based beverage effects on the gut microbiome in healthy adults

  This study tests how drinking different plant-based beverages for two weeks affects the gut microbiome in healthy adults.

  Recruiting Lund University · Lund, Skåne County · NCT07730229

• Inulin Prebiotic for Perimenopausal Women with Overweight or Obesity

  This study tests whether 2 weeks of inulin can affect gut and vaginal microbes, heart health, and muscle health in perimenopausal women who are overweight or obese, using a crossover design.

  Recruiting George Washington University · Washington D.C., District of Columbia · NCT07724522

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.